Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor.

Protein-protein interaction (PPI) systems represent a rich potential source of targets for drug discovery, but historically have proven to be difficult, particularly in the lead identification stage. Application of the fragment-based approach may help toward success with this target class. To provide an example toward understanding the potential issues associated with such an application, we have deconstructed one of the best established protein-protein inhibitors, the Nutlin series that inhibits the interaction between MDM2 and p53, into fragments, and surveyed the resulting binding properties using heteronuclear single quantum coherence nuclear magnetic resonance (HSQC NMR), surface plasmon resonance (SPR), and X-ray crystallography. We report the relative contributions toward binding affinity for each of the key substituents of the Nutlin molecule and show that this series could hypothetically have been discovered via a fragment approach. We find that the smallest fragment of Nutlin that retains binding accesses two subpockets of MDM2 and has a molecular weight at the high end of the range that normally defines fragments.

[1]  Olivier Sperandio,et al.  Rationalizing the chemical space of protein-protein interaction inhibitors. , 2010, Drug discovery today.

[2]  Andreas Thomann,et al.  Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. , 2012, Chemistry & biology.

[3]  Binh Vu,et al.  MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. , 2013, Cancer research.

[4]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[5]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[6]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[7]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[8]  P. Hajduk.  Fragment-based drug design: how big is too big? , 2006, Journal of medicinal chemistry.

[9]  Binh Vu,et al.  Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development. , 2013, ACS medicinal chemistry letters.

[10]  D. Lane,et al.  Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. , 1994, Oncogene.

[11]  Chris de Graaf,et al.  Ligand efficiency as a guide in fragment hit selection and optimization. , 2010, Drug discovery today. Technologies.

[12]  D. Scott,et al.  Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.

[13]  Andrew Pannifer,et al.  Using fragment-based technologies to target protein-protein interactions. , 2012, Current pharmaceutical design.

[14]  M. Williamson.  Using chemical shift perturbation to characterise ligand binding. , 2013, Progress in nuclear magnetic resonance spectroscopy.

[15]  S. Barelier,et al.  Fragment-based deconstruction of Bcl-xL inhibitors. , 2010, Journal of medicinal chemistry.

[16]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.